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A b s t r a c t  
Allium sativum [ASE] and Lagerstroemia speciosa [LSE] are widely used in folk medicine as a 
medication for diabetes. DIA-2 is a polyherbal antidiabetic formulation containing fixed combination 
[1:1 w/w] of standardized aqueous extracts of Allium sativum bulbs containing 1.1 % alliin w/w and 40 
% hydroalcholic extract of Lagerstroemia speciosa leaves containing 1.28% w/w corosolic acid. Earlier 
studies in our laboratories have demonstrated the oral safety of DIA-2 on acute oral exposure to 
female Sprague Dawley [SD] rats and the antidiabetic activity of DIA-2 in high-fat diet 
fed/streptozotocin-induced diabetic rats. The ingredients of DIA-2 have long history safety but 
however, there is little toxicological information regarding the oral safety on repeated exposure of ASE 
and LSE when given as a combined mixture. The present study evaluated the repeated oral toxicity of 
DIA-2 in both the sexes of SD rats.  Rats were treated orally once with 62.5, 125, 250 mg/kg body 
weight, and animals were observed till the 28 days of study. On repeated oral administration, DIA-2 
showed did not exhibit any clinical signs of toxicity, mortality, significant change in food, water 
consumption, body weight, mortality, clinical chemistry, hematology, organ weight, gross pathology 
and histopathology when varying doses of the DIA-2 were administered orally once daily for a period of 
28 days. The NOAEL [No Observed Adverse Effect Level] of DIA-2 in this study was identified to be 
greater than 250 mg/kg/day. The results from the study suggest that there are no toxicologically 
significant effects on 28 day repeated oral administration of DIA-2 and the data also provide 
satisfactory preclinical evidence on its oral safety to support its use as a therapeutic agent in the 
treatment of diabetes mellitus. 





Obesity and type 2 diabetes mellitus are two major metabolic 
disorders that are prevalent all over the world [1], in which obesity 
is strongly associated with incidence of type 2 diabetes mellitus 
[2].Insulin resistance syndrome appears to be the common 
contributing factors for most of the metabolic disorders [3]. Obesity 
is characterized by an increase in the adipose deposits, a condition 
that promotes the development of insulin resistance [4]. Controlling 
obesity represents an approach to decrease the degree of insulin 
resistance and delay the incidence of type 2 diabetes followed by 
its associated complications [5].  
Oral hypoglycemic agents (OHA)/insulin or both are prescribed in 
the therapeutic management of diabetes mellitus, but each class of 
drugs has its own side effects. Hypoglycemia and adiposity are the 
most common side effects shared by most classes of anti-
hyperglycemic agents. Hence, these agents treat the key symptom 
of diabetes [i.e. hyperglycemia] but aggravate the condition of 
adiposity and thus beneficial for short term use and not optimal for 
long term use [5]. Despite of their role in effective treatment of 
diabetes, most of the currently available OHA are still to be 
optimized. So there arises a need for better candidates [6].  
Several medicinal plants were being used as anti-diabetic 
therapies as part of our diet since prehistoric time [7]. Allium 
sativum [commonly known as garlic] and Lagerstroemia speciosa 
[also known as banaba] are one such dietary medicinal food used 
all over the world in the treatment of several disorders. Garlic and 
Banaba were shown to posses either antidiabetic effects [8; 5] or 
have direct effects on adipose tissue [9; 10]. Multiple therapeutic 
effects in the absence of toxicity can be achieved with plant drug 
combinations due to their diverse pharmacological actions [11]. 
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may show a great therapeutic potential in the management of 
obesity associated diabetes devoid of any side effects. Though 
garlic and banaba were used as dietary medicinal food traditionally, 
the general perception that these herbal drugs may be safe and 
free from toxicity may not be true, when given as a combination. 
Few studies on the toxicological profile of Allium sativum [12; 13; 
14; 15] were reported indicating the need for identification a safe 
dose range for garlic. In case of Lagerstroemia speciosa, there was 
no toxicity related information except few animal studies and 
clinical studies [16; 5]. The present study investigates the 
toxicological effects of DIA2, a polyherbal formulation consisting 
fixed combination [1:1 w/w] of standardized ingredients [ASE and 
LSE] after 28-day repeated oral administration in both the sexes of 
Sprague-Dawley rats. 
Materials and Methods 
Chemicals and reagents 
The diagnostic biochemical kits were purchased from Accurex 
Biomedical Pvt. Ltd., Mumbai, India. All other chemicals and 
reagents used in the study were of analytically grade.  
Plants extracts and preparation of DIA-2 
Authentic samples of ASE and LSE were obtained commercially 
from M/s. Amsar Pvt. Ltd, Indore, India and M/s. K.Patel, 
PhytoExtractions Pvt Ltd, Mumbai, India respectively. Both ASE 
and LSE has been standardized and optimized and claimed to 
contain 1.1 % alliin w/w and 1.28 % w/w corosolic acid 
respectively. In addition, the heavy metal content and microbial 
contaminants were within the permissible limits. Both the extracts 
were triturated individually to a fine powder using mortar and 
pestle, weighed and mixed uniformly in the ratio 1:1 w/w. The 
resulting powder mixture is called as DIA-2. DIA-2 suspension was 
prepared freshly daily using reverse osmosis water before dosing. 
Animals and husbandry 
Healthy young male and female Sprague dawley (SD) rats of body 
weight range 150 ± 20% mean were selected for the study. The 
animals were housed individually in sterile bedded polypropylene 
cages and provided with food (Nutrilab Rodent, Tetragon Chemie 
Pvt Ltd, India) and purified water ad libitum. They were kept in a 
well ventilated room (air exchange: 70:30; air cycles: 15/min) under 
a standard temperature of 23±2°C and 40–65% relative humidity, 
with a 12-h light/dark artificial cycle. All the animals were 
acclimatized for 7 days prior to the study. Guidelines of “Guide for 
the care and use of laboratory animals” (Institute of laboratory 
animal resources, National academic press 1996; NIH publication 
number #85-23, revised 1996) were strictly followed throughout the 
study. The study was approved by Institutional Animal Ethical 
Committee (IAEC), Sri Ramachandra University; Chennai, India 
(IAEC/XI/ SRMC & RI /61/2006). 
Repeated dose 28-day oral toxicity study 
The study was performed as per the Organisation for Economic 
Co-operation and Development (OECD) test guideline 407 
(Adopted: 3 October 2008). Both sexes of young healthy adult SD 
rats ranging from 140-160g were acclimatized individually in sterile 
polypropylene cages for 7 days. Our earlier study on acute oral 
toxicity studies indicated that acute oral LD50 of DIA-2 was greater 
than 2000 mg/kg in female SD rats and in another study using high 
fat (HFD)/streptozotocin (STZ) induced diabetic rat, DIA-2 was 
found to exhibit anti-diabetic activity without exhibiting any toxic 
signs as evidenced from the histopathological finding till the dose 
range of 125 mg/kg body weight. DIA-2 at 250 and 500 mg/kg body 
weight did not show any protection after 14 days of treatment in 
HFD/STZ induced diabetic rats [17].  On the basis of these results, 
three therapeutic doses of 62.5 mg/kg (Low dose), 125 mg/kg (Mid 
dose) and 250 mg/kg (High dose) were selected for the study. All 
the animals were randomized accordingly with their body weights 
into 4 groups of 10 animals each (5 males, 5 females/each group). 
Group I served as control which received vehicle at 10ml/kg body 
weight orally. Group II, III and IV received DIA-2 at 62.5 mg/kg, 125 
mg/kg and 250 mg/kg, per oral, respectively, for a period of 28 
days. The experimental animals received their respective 
treatments orally twice daily.  
Study design 
Clinical observations which include general behaviour, respiratory 
pattern, cardiovascular signs, motor activities, reflexes, changes in 
skin, fur and mortality signs were observed for all the experimental 
animals continuously at 30 min, 1h, 2h and 4h after the 
administration of the doses and thereafter once a day for 28 days 
preferably at the same time (1 hour after the dose administration). 
Body weights were taken on 0th, 1st, 7th, 14th, 21st and 28th days of 
dose administration. Individual doses were calculated based on the 
most recent weekly body weights and were adjusted each week to 
maintain the targeted dose level. Doses were administered to all 
groups at a constant dose volume of 10 ml/kg. Feed and water 
consumption was monitored and recorded throughout the study 
and was expressed as 7 day cumulative data.  
On the last day of dose administration all the animals were kept for 
overnight fasting (water ad libitum). The overnight fasted animals 
were anaesthetized under general anaesthesia using isoflourane, 
blood samples were collected using heparinised microhematocrit 
tubes by retro-orbital puncture into a potassium EDTA containing 
blood collection tubes (for haematological) and 11% w/v tri-sodium 
citrate (TSC) containing tubes (for biochemical fanalysis). Blood 
smear was prepared from the EDTA containing blood sample, air 
dried and stained (Hemacolor rapid staining of blood smear, 
E.Merck, Mumbai, India) for differential leukocyte count (DLC). 
Haematological analysis were performed using automated 
haematology analyzer (Model PE 6000 Rapid Diagnostics Pvt Ltd, 
New Delhi, India), which includes analysis of haemoglobin (HGB), 
red blood cell count (RBC), white blood cell count (WBC], platelet 
count and hematocrit (HCT).  
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The 11% TSC containing blood tubes were centrifuged 
immediately in refrigerated centrifuge (Model 5810 R, Eppendorf 
AG, Germany) at 1500 x g for 15 min. The plasma thus collected 
was analysed for glucose, triglyceride, cholesterol, alkaline 
phosphatase (ALP) aspartate transaminase (AST) alanine 
transaminase (ALT) lactate dehydrogenase (LDH), total bilirubin 
creatinine, urea, protein and albumin levels by using biochemical 
kits (Accurex Biomedical Pvt. Ltd, Thane, India) in semi automated 
biochemical analyzer (Model: Star 21 Plus, Rapid Diagnostics Pvt 
Ltd, New Delhi, India).  
Histopathology 
After blood collection, end terminal body weight measurements 
were made and all the experimental animals were sacrificed by 
cervical dislocation under general anaesthesia for gross 
pathological examination of all major internal organs. Organs like 
liver, kidneys, adrenals, brain, spleen, heart, lungs and 
testes/ovaries were dissected immediately after euthanasia, blotted 
free from blood and weighed. The major organs including liver, 
kidney, brain, heart testes, epididymis, prostate, seminal vesicle, 
uterus, ovary, thyroid and parathyroid were collected from vehicle 
control and high dose groups (250 mg/kg) and when appropriate 
from the lower dose groups (62.5 and 125 mg/kg). All the 
specimens were fixed in 10% neutral buffered formalin for 48 h. 
Thereafter the fixed tissues were processed for paraffin 
embedment, sectioned to 4 μm thick using the microtome (Leica 
RM2125RT, Germany). The sections were stained with 
haematoxylin and eosin (H&E) stain for general histopathological 
evaluation. 
Statistical analysis 
Data were expressed as mean ± standard error mean. Data 
obtained from repeated dose studies were analysed by Student’s t-
test using GraphPad prism 5.0 to determine significant difference 
between the means of control and test groups. p value ≤ 0.05 was 
considered significant. 
Results and Discussion 
Herbal medicines are consumed by humans either as food or 
medicine [18]. Allium sativum and Lagerstroemia speciosa are one 
such herbal medicine consumed either as food or medicine by 
humans for treating various disorders. Though the therapeutic 
effect of these medicinal plants in metabolic disorder management 
are established [16;19] but still there is limited or no scientific data 
regarding their safety aspects when given as a herbal mixture.  
High dose (500 mg/kg body weight/day) of Allium sativum has 
been reported for its hepatotoxic potential and low doses of garlic 
(100 or 250 mg/kg body weight/day) are considered to safe [20; 21; 
22]. High concentrations of triterpene acids, like corosolic acid 
have also been know for its toxic effects [23]. DIA-2 is a herbal 
mixture containing standardized extracts of Allium sativum and 
Lagerstroemia speciosa. The present study was undertaken to 
access the possible effects of DIA-2 after repeated oral 
administration for 28 days to either sex of SD rats.  
The determination of repeated oral toxicity of DIA-2 could be 
evaluated only after obtaining initial toxic information on its acute 
oral exposure. Our earlier study demonstrated the oral safety in 
female SD rats to ascertain the toxicity related information after 
single administration of DIA-2 at a dose (2000 mg/kg) 
recommended by OECD-423 test guideline. The absence of clinical 
signs of toxicity, lack of changes in body weight and gross 
pathology of vital organs on necropsy suggested that DIA-2 is 
orally safe up to 2000 mg/kg body weight [17]. 
The selection of dose for the study is based on the therapeutic 
dose of DIA-2. The low dose (62.5 mg/kg), high dose (250 mg/kg) 
is selected based on its anti-hyperglycemic effect as investigated in 
our earlier study [17] and the intermediate dose (125 mg/kg) is a 
geometric mean between the high and the low dose. Administration 
of DIA-2 at these selected dose levels for 28 days to either sex of 
SD rats showed no treatment related changes regarding clinical 
signs, mortality, body weights, feed and water consumption, 
hematology, clinical chemistry, organ weight, gross and 
histopathology in rats of either sex. 
Clinical signs are used as a measure of humane endpoints in 
safety evaluation studies; administration of DIA-2 did not produce 
any toxic clinical signs or mortality during the experimental period. 
Weekly changes in body weights are shown in fig-1, which 
revealed that administration of DIA-2 had no significant effect on 
the body weight in either sex when compared to vehicle control 
group. No significant difference was also observed on weekly feed 
[fig-2] and water consumption [fig-3] between the DIA-2 and vehicle 
treated groups. 
Few studies on garlic use have reported to cause allergic 
reactions, alteration of platelet functions [24], however the platelet 
function is not impaired by single and repeated oral consumption at 
dietary dose [25]. The effect of DIA-2 on haematological test 
performed at the end of the study did not differ between groups 
[table-1]. DIA-2 treatment also showed no significant changes in 
plasma biochemistry compared to the control group [table-2]. 
Organ weight data’s obtained from toxicology studies is an integral 
component in the safety assessment of pharmaceuticals [26] and 
food/nutritional products [27]. The organ weight is considered to be 
an important endpoint for identification of toxic effects of chemicals 
on target organs [28]. The relative organ weight (organ weight 
expressed as a percentage of body weight) was calculated from 
the terminal body weight and shown in table-3. There was no 
significant difference in relative organ weight in either sexes of rats 
in both DIA-2 and vehicle treated animal groups. 
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Fig-1: Effect of repeated administration of DIA-2 on body weight of male (left) and female (right) Sprague Dawley rats. Values are expressed in 
mean ± SEM (n=5); Statistical analysis was performed with Student‘t’ test following one way ANOVA using GraphPad prism 5.0 
 
 
Fig-2: Effect of repeated administration of DIA-2 on feed consumption of male (left) and female (right) Sprague Dawley rats. Values are 
expressed in mean ± SEM (n=5); Statistical analysis was performed with Student‘t’ test following one way ANOVA using GraphPad prism 5.0 
 
 
Fig-3: Effect of repeated administration of DIA-2 on water consumption of male (left) and female (right) Sprague Dawley rats. Values are 
expressed in mean ± SEM (n=5); Statistical analysis was performed with Student‘t’ test following one way ANOVA using GraphPad prism 5.0 
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Histopathological examinations of the major organs [liver, kidney, 
brain, heart] were shown in fig-4. The histological changes of  
 
sexual organs of male and female rats and endocrine gland, 
thyroid were shown in fig-5-6. On histological examination of all the  
 
Table.1: Effect of repeated administration of DIA-2 on haematology of male and female Sprague Dawley rats 
 










White Blood Cells 
(103μL) 
M 11.40±1.83 7.86 ± 0.41 9.75 ± 1.85 9.96 ± 1.31 
F 7.30 ± 1.07 7.22 ± 1.11 6.76 ± 0.61 9.16 ± 0.61 
Red Blood Cell 
(106μL) 
M 7.57 ± 0.63 6.14 ± 0.59 6.82 ± 0.74 5.30±0.16 
F 6.49 ± 0.73 5.42 ± 0.63 5.92 ± 0.60 5.86 ± 0.69 
Hemoglobin (g/dL) 










































M 16.20±2.48 17.60±0.93 17.23±1.28 20.80±2.08 
F 17.80±3.68 17.40±1.36 17.40±0.60 18.80±2.35 
Eosinophil (%) 
M 1.60±0.51 2.20±0.66 2.00±0.71 2.08±0.28 
F 1.40±0.51 2.10±0.64 1.84±0.30 2.12±0.31 
Basophil (%) 
M 0.40±0.24 1.00±0.32 0.62±0.15 0.62±0.08 
F 0.80±0.37 0.26±0.08 0.46±0.10 0.70±0.11 
Monocytes (%) 
M 2.20±0.37 2.40±0.68 1.80±0.37 1.80±0.58 
F 1.60±0.51 2.20±0.58 2.20±0.58 2.00±0.45 
 
 
Values are expressed in mean ± SEM (n=5); Statistical analysis was performed with Student‘t’ test following one way ANOVA using GraphPad 
prism 5.0 
 
organs in high dose of DIA-2 (250 mg/kg body weight) treated 
animals, exhibited no apparent pathological alterations when 
compared to vehicle treated animals. 
In the safety assessment of chemicals to humans, it is essential to 
determine no-observed-adverse-effect-levels (NOAEL) or lowest-
observed-adverse-effect-levels (LOAEL) from animal experiments 
[29]. The lowest-observed adverse effect level (LOAEL) of DIA-2 
was ≥ 250 mg/kg and the no-observed adverse effect level 
(NOAEL) was ≤ 125 mg/kg. 
In conclusion, our results showed that there was no treatment-
related toxicity in rats of either sex following 28-days oral 
administration of 62.5, 125 and 250 mg/kg body weight of DIA-2. 
DIA-2 is found to be orally safe under the tested experimental 
condition. The data’s obtained from the study supports the potential 
use of DIA-2 as a medicinal food or dietary supplement in the 
management of diabetes.. 
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Table.2: Effect of repeated administration of DIA-2 on plasma biochemistry of male and female Sprague Dawley rats 


























Water ( 10 ml/kg) 
M 97.72±13.02 51.62±8.83 48.28±7.96 178.54±25.62 109.15±16.64 39.27±12.87 371.17±14.29 0.03±0.01 1.70±0.07 10.51±2.95 4.91±0.09 1.96±0.11 
F 115.06±6.53 39.43±3.56 98.43±14.57 184.40±49.10 80.75±4.07 34.12±2.55 270.60±28.39 0.05±0.01 1.60±0.03 15.46±0.90 5.42±0.45 2.21±0.16 
DIA-2 
(62.5 mg/kg) 
M 76.61±6.38 56.50±5.41 72.51±7.22 261.12±27.36 91.11±4.61 47.94±5.31 272.68±38.35 0.03±0.01 1.61±0.04 14.09±1.03 5.22±0.27 2.05±0.15 
F 116.72±3.84 36.24±2.46 81.35±9.81 270.52±46.62 110.93±10.82 44.79±3.97 360.18±31.77 0.06±0.02 1.63±0.03 18.41±1.03 5.75±0.30 2.13±0.14 
DIA-2 
(125 mg/kg) 
M 94.63±3.05 44.84±8.88 57.50±3.75 257.52±11.60 101.42±3.51 46.69±6.01 274.84±25.60 0.02±0.01 1.62±0.04 12.78±0.79 4.97±0.18 2.06±0.17 
F 107.26±3.43 45.17±5.16 75.79±5.16 313.40±45.23 111.44±15.98 41.99±2.26 370.70±48.20 0.03±0.01 1.70±0.07 18.82±1.16 5.75±0.36 2.36±0.20 
DIA-2 
(250 mg/kg) 
M 103.40±2.56 45.57±3.13 56.56±2.21 264.46±39.16 101.75±9.23 59.15±16.84 290.40±37.44 0.03±0.01 1.60±0.04 16.31±1.64 5.20±0.38 1.94±0.15 
F 109.92±6.02 39.21±2.99 71.20±4.95 155.87±12.40 118.90±10.47 43.93±6.16 345.08±48.82 0.05±0.00 1.65±0.09 20.10±1.14 5.97±0.15 2.42±0.10 
Values are expressed in mean ± SEM (n=5); Statistical analysis was performed with Student‘t’ test following one way ANOVA using GraphPad prism 5.0 
 
Table.3: Effect of repeated administration of DIA-2 on relative organ weight of male and female Sprague Dawley rats 
 
Dose Sex 
Organ Weight (gm) 
 Body Weight Liver Kidneys Adrenal Brain Spleen Heart Lung Testes/Ovary 
Control 
Male 242.2 ± 9.02 8.10±0.20 1.94 ± 0.06 0.06 ± 0.00 1.34 ± 0.06 1.10 ± 0.11 0.99 ± 0.08 1.49 ± 0.20 4.33±0.06 
Female 193.80 ± 3.07 6.90 ± 0.29 1.43 ± 0.02 0.04 ± 0.00 1.25 ± 0.02 0.95 ± 0.10 0.78 ± 0.04 1.43 ± 0.03 0.08 ± 0.01 
DIA-2 
(62.5mg/kg) 
Male 245.40±5.80 7.84±0.10 2.00±0.09 0.06±0.01 1.36±0.01 0.96±0.08 0.89±0.03 1.52±0.09 4.11±0.02 
Female 180.60 ±6.47 6.70 ±0.41 1.49 ±0.06 0.05 ±0.01 1.29 ±0.02 0.81±0.08 0.77 ±0.02 1.65 ±0.15 0.06 ±0.01 
DIA-2 
(125mg/kg) 
Male 236.75 ± 6.80 7.81 ± 0.30 1.75 ± 0.05 0.05 ± 0.00 1.41 ± 0.07 0.99 ± 0.09 0.88 ± 0.03 1.74 ± 0.06 4.15 ± 0.14 
Female 186.60 ± 5.94 6.99 ± 0.23 1.43 ± 0.03 0.06 ± 0.01 1.28 ± 0.02 0.91 ± 0.06 0.70 ± 0.03 1.46 ± 0.08 0.11 ± 0.02 
DIA-2 
(250mg/kg) 
Male 233.25 ± 3.00 7.80 ± 0.19 1.73 ± 0.02 0.05 ± 0.01 1.35 ± 0.04 1.17 ± 0.05 0.89 ± 0.03 1.49 ± 0.04 4.14 ± 0.14 
Female 190.20±2.60 7.22±0.20 1.48±0.03 0.05±0.00 1.28±0.01 1.01±0.02 0.70±0.04 1.49±0.03 0.10±0.01 
Values are expressed in mean ± SEM (n=5); Statistical analysis was performed with Student‘t’ test following one way ANOVA using GraphPad prism 5.0 
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Fig-4: Color plate of liver (a, b) kidney (c, d) brain (e, f) and heart (g, h) histopathology from representative animals of vehicle treated control group and high dose of DIA-2 (250 
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Fig-5: Color plate of testes (a, b), Epididymis (c, d), prostate (e, f) and seminal vesicle (g, h) histopathology from representative animals of vehicle treated control group and high dose 
of DIA-2 (250 mg/kg/day) group (hematoxylin–eosin stain). 
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Fig-6: Color plate of uterus (a, d), ovary (c, d), thyroid (e,f) and parathyroid (g,h) histopathology from representative animals of vehicle treated control group and high dose of DIA-2 
(250 mg/kg/day) group (hematoxylin–eosin stain).  
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